Skip to main content
Premium Trial:

Request an Annual Quote

CosmosID, Resilient Biotics Form Respiratory Microbiome Research Alliance

NEW YORK — Resilient Biotics said on Thursday that it has partnered with CosmosID to investigate the respiratory tract microbiome and its role in human health.

Under the alliance, the companies will identify and analyze respiratory tract microbiome systems across multiple animal models, using CosmosID's sequencing facility and bioinformatics expertise with respiratory colonizers in Resilient's strain collection.

Financial and other terms were not disclosed.

"Our collaboration aims to deepen our understanding of the respiratory tract's microbiome, which could redefine the future of respiratory health management," CosmosID President Manoj Dadlani said in a statement.

Germantown, Maryland-based CosmosID merged with Danish microbiome informatics firm Clinical Microbiomics A/S in late 2023.

Resilient, headquartered in Durham, North Carolina, was a member of Illumina's accelerator program.